Eversept Partners LP Has $138.79 Million Position in Natera, Inc. (NASDAQ:NTRA)

Eversept Partners LP grew its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 876,766 shares of the medical research company's stock after purchasing an additional 6,573 shares during the period. Natera makes up approximately 12.3% of Eversept Partners LP's holdings, making the stock its largest holding. Eversept Partners LP owned approximately 0.66% of Natera worth $138,792,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. MML Investors Services LLC grew its stake in Natera by 34.6% during the third quarter. MML Investors Services LLC now owns 4,593 shares of the medical research company's stock worth $583,000 after buying an additional 1,180 shares during the period. Sanctuary Advisors LLC grew its holdings in Natera by 113.1% during the 3rd quarter. Sanctuary Advisors LLC now owns 7,486 shares of the medical research company's stock valued at $950,000 after purchasing an additional 3,973 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Natera during the third quarter worth about $385,000. Franklin Resources Inc. increased its holdings in Natera by 42.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company's stock worth $144,958,000 after purchasing an additional 328,375 shares during the last quarter. Finally, Exome Asset Management LLC raised its position in shares of Natera by 20.4% in the 3rd quarter. Exome Asset Management LLC now owns 22,450 shares of the medical research company's stock valued at $2,850,000 after purchasing an additional 3,800 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the completion of the sale, the chief financial officer now directly owns 75,557 shares of the company's stock, valued at approximately $10,457,844.37. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the completion of the sale, the director now directly owns 9,704 shares of the company's stock, valued at approximately $1,433,183.76. The trade was a 29.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 198,743 shares of company stock valued at $30,558,447 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Natera Stock Down 0.4 %

Shares of NTRA stock traded down $0.69 during trading hours on Friday, hitting $153.79. 806,949 shares of the company were exchanged, compared to its average volume of 1,379,927. Natera, Inc. has a 52 week low of $90.88 and a 52 week high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of $147.95 and a two-hundred day moving average of $153.34. The company has a market capitalization of $20.79 billion, a PE ratio of -87.38 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NTRA. Guggenheim lifted their price target on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Sanford C. Bernstein increased their price target on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. Piper Sandler upped their price objective on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $175.76.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.